Exercise coaching may ease fatigue during radiation for endometrial cancer
NCT ID NCT06746428
First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 4 times
Summary
This study tests whether a personalized activity coaching program can help women feel less tired during pelvic radiation therapy for endometrial cancer. Sixteen participants will be randomly assigned to receive coaching or usual care. The main goal is to see if the program is practical and helpful for managing treatment-related fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 16 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * At least 18 years of age * Pathologic diagnosis of endometrial cancer (any histology, Stage I-IVA) * Has undergone modified radical or radical hysterectomy * Plan to receive adjuvant treatment with pelvic external beam radiation therapy at ISCI * ECOG performance status of 0-1 * Patient has a computer, smart phone, or tablet virtual access to the web-based platform and email * Able to read, understand and provide written informed consent * Deemed appropriate for unmonitored exercise by treating physician based on the following evidence-based criteria (1) * Walk without any assistance or assistance device * Absence of significant cognitive impairment * Absence of high risk for falls * Participant does not need to refrain from any activity Exclusion Criteria: * Unable to schedule and attend coaching visits * Participation in a regular exercise program of ≥150 minutes of moderate intensity exercise a week at baseline * Unable to perform the five-times stand test * Medical comorbidities including: * Unstable angina * Uncontrolled dysrhythmias * Acute pulmonary embolus * Active pulmonary infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Inova Schar Cancer Institute - Alexandria
Alexandria, Virginia, 22311, United States
-
Inova Schar Cancer Institute - Fair Oaks
Fairfax, Virginia, 22033, United States
-
Inova Schar Cancer Institute - Loudoun
Leesburg, Virginia, 20176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
- Your gut bacteria may hold the key to whether immunotherapy works
- Can precision radiation and immunotherapy team up against abdominal colorectal cancer?
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?